💸 The Tape

Organigram Holdings Inc. (NASDAQ: OGI; TSX: OGI) has kicked off Fiscal 2025 with a flourish, posting a 17% year-over-year net revenue jump to $42.7 million—an impressive feat in an ever-competitive cannabis market. Topping it off, the newly acquired Motif Labs contributed to these results within just 25 days of ownership, pointing to the kind of rapid synergy that shareholders were looking for. CEO Beena Goldenberg credits this momentum to an all-in focus on efficiency, innovation, and deeper global reach.

Behind the scenes, the Motif integration is cruising along. Management projects more than $10 million in annual run-rate synergies over the next two years—capitalizing on Motif’s processing capabilities to broaden Organigram’s already diverse product portfolio. Combine that with a negligible debt load and a pro-forma cash position of about $113 million upon the completion of BAT’s upcoming $41.5 million follow-on investment, and the balance sheet is sitting pretty for global expansion.

Speaking of global, Organigram’s sights are set firmly on Europe and beyond. A recent $21 million stake in Germany’s Sanity Group cements the company’s foothold in a market that’s blossomed fourfold since April 2024. And it’s not just about Europe: Organigram’s new “Jupiter” investment pool has already deployed capital into other ventures like U.S.-based Open Book Extracts. All of this underscores the company’s broader strategy to leverage an increasingly international cannabis landscape.

Innovation remains a cornerstone of Organigram’s approach. Edison Sonics gummies, powered by the PDC with BAT, offer faster onset and nearly double the cannabinoid concentration at peak vs. traditional edibles—music to consumers’ ears. The pipeline includes everything from SHRED Captain Kush Dartz to premium Wô Là Black Cherry Punch, catering to a wide range of tastes.

With improved cultivation efficiency, strong international partnerships, a robust product lineup, and a war chest of capital in the wings, Organigram is poised for continued success in the evolving cannabis sector. For investors eyeing a juggernaut with both domestic dominance and international ambition, this quarter’s numbers might be the green light they’ve been waiting for.

📈 Dog Walkers

Movement In Florida

Sunshine State lawmakers are betting on an expanded medical cannabis jackpot, courtesy of Sen. Joe Gruters’s fresh SB 552. This measure opens doors for patients with opioid prescriptions, scraps fees for veterans, and welcomes out-of-staters, effectively turning Florida into a potential medical marijuana hotspot. Telehealth visits are now fair game for doctor recommendations, plus patients only need to renew their registration every two years. Meanwhile, SB 456 outlines a carefully monitored homegrow option—two plants, enclosed and landlord-approved. Mix that with pending bills safeguarding parental rights and government job security, and Florida might just lure an even bigger green wave soon.

From His Lips To Gods Ears

Rep. Warren Davidson (R-OH) believes Congress can finally pass a marijuana banking bill, contending that financial barriers constitute a “second tier” of prohibition. During a House Financial Services Committee hearing, he bemoaned the debanking of investors, employees, and businesses in a lawfully recognized sector. Discussing risk analysis, Better Markets’ Shayna Olesiuk argued legitimate enterprises should have banking access. Davidson hinted at the SAFE Banking Act as a solution, hoping that congressional focus on broader debanking issues will help push cannabis finance reform across the finish line.

One Step Forward Five Steps Back

New York cannabis labs are raising red flags over inflated THC potency and suspicious vape oil profiles. Biotrax Testing Laboratory and Certified Testing & Data allege “no place for such behavior,” warning trust is on the line. Meanwhile, the Office of Cannabis Management is apparently brushing off concerns, and lab data sets remain MIA. Some claim certain labs offer “high potency” guarantees—for a price. This situation has critics calling for immediate recalls and stricter oversight to avert an industry confidence crisis.

🗞️ The News

Organigram Reports First Quarter Fiscal 2025 Results

Washington Bills To Legalize Psilocybin Get Critical Reception During Public Hearings

Federal Appeals Court Says Constitution Doesn’t Support Taking Guns Away From All Marijuana Users Categorically

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

CSE Bulletin: Name and Symbol Change - Cansortium Inc. (TIUM.U)

📺 YouTube

Could We See a Direct Ruling on Cannabis Rescheduling? | Trade to Black

What we covered:

✅ On our latest Trade To Black at 4 p.m. EST, host Shadd Dales and Anthony Varrell will once again be joined by Shane Pennington, Partner at Porter Wright Morris & Arthur LLP, to talk about the ongoing ALJ Hearing related to the rescheduling of cannabis in the United States of America.

We'll ask if there have been any updates, and if the Trump administration could go for a direct ruling on the rescheduling of cannabis, and if so, what would need to happen in that scenario.

Plus, Michael Bronstein, President of the American Trade Association for Cannabis & Hemp will join us again for our new weekly segment, Insider Edge, to talk about the latest news from Pennsylvania involving adult use cannabis within the state.

News came out last week involving a Republican senator who supports marijuana legalization and said the governor’s latest cannabis proposal “undermines” the goals of the reform and has “no real path forward.”

While Sen. Dan Laughlin (R) has long advocated for legalization, sponsoring bipartisan bills to end prohibition, he said on Wednesday that Gov. Josh Shapiro’s (D) budget proposal to enact the policy change is fundamentally flawed.